Incretin science moved fast over the last year. Between December 2025 and April 2026 the U.S. FDA approved three new obesity medicines - all of them finished prescription drugs, none of them research chemicals. Understanding the difference matters, because the same molecule names circulate in very different contexts.
What the FDA approved
- Oral semaglutide (Wegovy pill, 25 mg) - approved 22 December 2025 as the first oral GLP-1 receptor agonist for chronic weight management.
- High-dose semaglutide (Wegovy HD, 7.2 mg injection) - approved 19 March 2026; the STEP UP trial reported about 20.7% mean weight loss at 72 weeks.
- Orforglipron (Foundayo, Eli Lilly) - approved 1 April 2026, the first oral non-peptide GLP-1 receptor agonist for obesity, taken without water or fasting restrictions.
Approved medicine vs research compound
An FDA approval applies to a specific finished product - a defined molecule, formulation, strength and manufacturer, prescribed and dispensed under medical supervision. It does not make the underlying peptide a consumer product, and it does not apply to material sold for laboratory research. A research-grade vial is characterised by its certificate of analysis - identity, purity, batch - not by a therapeutic indication.
Where retatrutide stands
Retatrutide (Eli Lilly's LY3437943) is frequently discussed alongside these approvals, but as of July 2026 it remains investigational in Phase 3 trials and is not FDA approved. Its TRIUMPH programme is expected to complete around late 2026 to early 2027. We cover its trial data in a separate article.
This article is scientific and regulatory information about compounds studied in research. It is not medical advice and makes no claim of any effect in humans. All products sold by Cryopept Labs are for laboratory research use only - not for human or veterinary use.